wikidoc - Recent changes [en]

Rgt1p gene transcriptions

2026-04-26T09:27:38Z

RGT samplings

← Older revision		Revision as of 09:27, 26 April 2026
Line 45:		Line 45:

	==RGT samplings==		==RGT samplings==
			[[Rgt1p gene transcriptions#RGT samplings\|RGT samplings]]

	Copying a responsive elements consensus sequence CGGAACTA or CGGGACTT and putting the sequence in "⌘F" finds none between ZNF497 and A1BG or none between ZSCAN22 and A1BG as can be found by the computer programs.		Copying a responsive elements consensus sequence CGGAACTA or CGGGACTT and putting the sequence in "⌘F" finds none between ZNF497 and A1BG or none between ZSCAN22 and A1BG as can be found by the computer programs.

GLM box gene transcriptions

2026-04-26T05:58:03Z

GLM box sampling of A1BG promoters

← Older revision		Revision as of 05:58, 26 April 2026
Line 28:		Line 28:

	==GLM box sampling of A1BG promoters==		==GLM box sampling of A1BG promoters==
			[[GLM box gene transcriptions#GLM box sampling of A1BG promoters\|GLM box sampling of A1BG promoters]]

	For the Basic programs (starting with SuccessablesGLM.bas) written to compare nucleotide sequences with the sequences on either the template strand (-), or coding strand (+), of the DNA, in the negative direction (-), or the positive direction (+), including extending the number of nts from 958 to 4445, the programs are, are looking for, and found:		For the Basic programs (starting with SuccessablesGLM.bas) written to compare nucleotide sequences with the sequences on either the template strand (-), or coding strand (+), of the DNA, in the negative direction (-), or the positive direction (+), including extending the number of nts from 958 to 4445, the programs are, are looking for, and found:

Chronic stable angina overview

2026-04-25T15:44:25Z

Treatment

Show changes

Cardiomyopathy overview

2026-04-25T14:08:19Z

← Older revision		Revision as of 14:08, 25 April 2026
(15 intermediate revisions by the same user not shown)
Line 1:		Line 1:
	__NOTOC__		__NOTOC__
	{{Cardiomyopathy}}		{{Cardiomyopathy}}
	{{CMG}}; {{AE}} {{EdzelCo}}		{{CMG}}; {{AE}} {{EdzelCo}} {{MSD}}

	==Overview==		==Overview==
Line 29:		Line 29:
	==Treatment==		==Treatment==
	===Medical Therapy===		===Medical Therapy===
	Treatment ~~depends~~ on the ~~type~~ of cardiomyopathy, ~~but may include medication~~, ~~implanted [[artificial pacemaker\|pacemakers]]~~, ~~[[Implantable cardioverter~~-~~defibrillator~~\|~~defribillators]]~~, ~~or [[ventricular assist device]]s (LVADs)~~, ~~or [[ablation]]~~. ~~The goal of treatment is often~~ symptom relief, and ~~some~~ patients ~~may eventually require a [[~~heart transplant]]. ~~Treatment~~ of ~~cardiomyopathy (~~and ~~other heart diseases) using alternative methods such as [[stem cell therapy]] is commercially available but is not supported by convincing evidence~~.		Treatment is phenotype-directed and includes guideline-directed medical therapy (GDMT) for heart failure syndromes and targeted therapy for specific cardiomyopathies such as hypertrophic cardiomyopathy (HCM). In HCM, management includes symptom-directed pharmacotherapy (beta-blocker or nondihydropyridine calcium-channel blocker, with disopyramide or a cardiac myosin inhibitor in selected adults with obstructive physiology), risk-based use of ICDs, and septal reduction therapy at experienced centers when symptoms persist despite medical therapy.<ref name="pmid38718139">{{cite journal \|vauthors=Ommen SR, Ho CY, Asif IM, Balaji S, Burke MA, Day SM, Dearani JA, Epps KC, Evanovich L, Ferrari VA, Joglar JA, Khan SS, Kim JJ, Kittleson MM, Krittanawong C, Martinez MW, Mital S, Naidu SS, Saberi S, Semsarian C, Times S, Waldman CB \|title=2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines \|journal=Circulation \|volume=149 \|issue=23 \|pages=e1239–e1311 \|date=June 2024 \|pmid=38718139 \|doi=10.1161/CIR.0000000000001250 \|url=}}</ref> <ref name="pmid35363499">{{cite journal \|vauthors=Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW \|title=2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines \|journal=Circulation \|volume=145 \|issue=18 \|pages=e895–e1032 \|date=May 2022 \|pmid=35363499 \|doi=10.1161/CIR.0000000000001063 \|url=}}</ref>For cardiomyopathy with HFrEF, foundational GDMT consists of an ARNI/ACE inhibitor/ARB, evidence-based beta-blocker, mineralocorticoid receptor antagonist, and SGLT2 inhibitor, with additional therapies and device-based treatment individualized by EF, QRS, symptoms, and comorbidities.<ref name="pmid35363499">{{cite journal \|vauthors=Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW \|title=2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines \|journal=Circulation \|volume=145 \|issue=18 \|pages=e895–e1032 \|date=May 2022 \|pmid=35363499 \|doi=10.1161/CIR.0000000000001063 \|url=}}</ref> Goals include symptom relief, prevention of sudden cardiac death (when relevant, e.g., HCM), and modification of heart-failure trajectory; patients with advanced heart failure despite GDMT should be referred to an advanced HF team for consideration of transplant and/or durable mechanical circulatory support.<ref name="pmid35363500">{{cite journal \|vauthors=Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW \|title=2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines \|journal=Circulation \|volume=145 \|issue=18 \|pages=e876–e894 \|date=May 2022 \|pmid=35363500 \|doi=10.1161/CIR.0000000000001062 \|url=}}</ref> In HCM with atrial fibrillation, oral anticoagulation is recommended irrespective of CHA₂DS₂-VASc, and rhythm and/or rate control should be individualized.<ref name="pmid38718139">{{cite journal \|vauthors=Ommen SR, Ho CY, Asif IM, Balaji S, Burke MA, Day SM, Dearani JA, Epps KC, Evanovich L, Ferrari VA, Joglar JA, Khan SS, Kim JJ, Kittleson MM, Krittanawong C, Martinez MW, Mital S, Naidu SS, Saberi S, Semsarian C, Times S, Waldman CB \|title=2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines \|journal=Circulation \|volume=149 \|issue=23 \|pages=e1239–e1311 \|date=June 2024 \|pmid=38718139 \|doi=10.1161/CIR.0000000000001250 \|url=}}</ref>

	===Surgery===		===Surgery===
	~~There~~ are ~~several types~~ of ~~surgery used~~ to ~~treat cardiomyopathy. They include~~ septal ablation, ~~[[septal myectomy]]~~, ~~surgically implanted devices to improve~~ the ~~function~~ of the ~~heart~~, ~~and [[heart transplant]]~~.		Procedural and surgical options are phenotype-specific and should be performed at experienced centers when indicated.<ref name="pmid38718139">{{cite journal \|vauthors=Ommen SR, Ho CY, Asif IM, Balaji S, Burke MA, Day SM, Dearani JA, Epps KC, Evanovich L, Ferrari VA, Joglar JA, Khan SS, Kim JJ, Kittleson MM, Krittanawong C, Martinez MW, Mital S, Naidu SS, Saberi S, Semsarian C, Times S, Waldman CB \|title=2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines \|journal=Circulation \|volume=149 \|issue=23 \|pages=e1239–e1311 \|date=June 2024 \|pmid=38718139 \|doi=10.1161/CIR.0000000000001250 \|url=}}</ref> For symptomatic obstructive HCM refractory to medical therapy, septal reduction therapy includes surgical septal myectomy or (in selected patients) alcohol septal ablation. Advanced heart failure may require durable mechanical circulatory support and/or heart transplantation after evaluation by an advanced HF team.<ref name="pmid38718139">{{cite journal \|vauthors=Ommen SR, Ho CY, Asif IM, Balaji S, Burke MA, Day SM, Dearani JA, Epps KC, Evanovich L, Ferrari VA, Joglar JA, Khan SS, Kim JJ, Kittleson MM, Krittanawong C, Martinez MW, Mital S, Naidu SS, Saberi S, Semsarian C, Times S, Waldman CB \|title=2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines \|journal=Circulation \|volume=149 \|issue=23 \|pages=e1239–e1311 \|date=June 2024 \|pmid=38718139 \|doi=10.1161/CIR.0000000000001250 \|url=}}</ref><ref name="pmid35363500">{{cite journal \|vauthors=Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW \|title=2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines \|journal=Circulation \|volume=145 \|issue=18 \|pages=e876–e894 \|date=May 2022 \|pmid=35363500 \|doi=10.1161/CIR.0000000000001062 \|url=}}</ref>

	===Primary Prevention===		===Primary Prevention===
	~~Methods of primary~~ prevention ~~for cardiomyopathy include; maintaining a healthy weight~~, ~~not smoking~~, ~~avoiding~~ alcohol and illicit drugs, ~~reducing stress~~, and ~~treating underlying conditions such as [[diabetes]] and [[high blood pressure]]~~.		Primary prevention focuses on ‘at risk’ (Stage A) and ‘pre-HF’ (Stage B) management: control hypertension, diabetes, obesity, and other cardiovascular risk factors; avoid cardiotoxins (including excess alcohol and illicit drugs); and treat structural heart disease early to prevent progression to symptomatic HF.<ref name="pmid35363500">{{cite journal \|vauthors=Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW \|title=2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines \|journal=Circulation \|volume=145 \|issue=18 \|pages=e876–e894 \|date=May 2022 \|pmid=35363500 \|doi=10.1161/CIR.0000000000001062 \|url=}}</ref><ref name="pmid38033089">{{cite journal \|vauthors=Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, Deswal A, Eckhardt LL, Goldberger ZD, Gopinathannair R, Gorenek B, Hess PL, Hlatky M, Hogan G, Ibeh C, Indik JH, Kido K, Kusumoto F, Link MS, Linta KT, Marcus GM, McCarthy PM, Patel N, Patton KK, Perez MV, Piccini JP, Russo AM, Sanders P, Streur MM, Thomas KL, Times S, Tisdale JE, Valente AM, Van Wagoner DR \|title=2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines \|journal=Circulation \|volume=149 \|issue=1 \|pages=e1–e156 \|date=January 2024 \|pmid=38033089 \|pmc=11095842 \|doi=10.1161/CIR.0000000000001193 \|url=}}</ref>

	==Preferences==		==Preferences==

GARE gene transcriptions

2026-04-25T08:37:54Z

GARE-like 2 samplings

← Older revision		Revision as of 08:37, 25 April 2026
(One intermediate revision by the same user not shown)
Line 232:		Line 232:

	==GARE-like 1 samplings==		==GARE-like 1 samplings==
			[[GARE gene transcriptions#GARE-like 1 samplings\|GARE-like 1 samplings]]

	Copying a responsive elements consensus sequence TAACA(A/G)A and putting the sequence in "⌘F" finds none between ZNF497 and A1BG or one between ZSCAN22 and A1BG as can be found by the computer programs.		Copying a responsive elements consensus sequence TAACA(A/G)A and putting the sequence in "⌘F" finds none between ZNF497 and A1BG or one between ZSCAN22 and A1BG as can be found by the computer programs.
Line 369:		Line 370:
	==GARE-like 2 samplings==		==GARE-like 2 samplings==
	{{main\|Model samplings}}		{{main\|Model samplings}}
			[[GARE gene transcriptions#GARE-like 2 samplings\|GARE-like 2 samplings]]

	Copying a responsive elements consensus sequence TAACGTA and putting the sequence in "⌘F" finds none between ZNF497 and A1BG or none between ZSCAN22 and A1BG as can be found by the computer programs.		Copying a responsive elements consensus sequence TAACGTA and putting the sequence in "⌘F" finds none between ZNF497 and A1BG or none between ZSCAN22 and A1BG as can be found by the computer programs.

GGC triplet gene transcriptions

2026-04-25T08:13:04Z

GGC samplings

← Older revision		Revision as of 08:13, 25 April 2026
Line 440:		Line 440:

	==GGC samplings==		==GGC samplings==
			[[GGC triplet gene transcriptions#GGC samplings\|GGC samplings]]

	Copying a responsive elements consensus sequence GGC and putting the sequence in "⌘F" finds 145 + 57 between ZNF497 and A1BG or 17 + 121 between ZSCAN22 and A1BG as can be found by the computer programs.		Copying a responsive elements consensus sequence GGC and putting the sequence in "⌘F" finds 145 + 57 between ZNF497 and A1BG or 17 + 121 between ZSCAN22 and A1BG as can be found by the computer programs.

Datopotamab deruxtecan-dlnk

2026-04-25T05:40:10Z

Show changes

Datopotamab deruxtecan-dlnk

2026-04-25T03:20:50Z

Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |genericName=DATROWAY |aOrAn=a |drugClass=Trop-2-directed antibody and topoisomerase inhibitor conjugate |indicationType=treatment |indication=DATROWAY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of: 1. Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) DATROWAY is indicated for the treatment of adult patients with locally advanced or metastati..."

Show changes

GGC triplet gene transcriptions

2026-04-24T08:54:17Z

GGCGGC triplet samplings

← Older revision		Revision as of 08:54, 24 April 2026
Line 260:		Line 260:

	==GGCGGC triplet samplings==		==GGCGGC triplet samplings==
			[[GGC triplet gene transcriptions#GGCGGC triplet samplings\|GGCGGC triplet samplings]]

	# Negative strand, negative direction, looking for GGCGGC, 0.		# Negative strand, negative direction, looking for GGCGGC, 0.

Gcn4p gene transcriptions

2026-04-23T20:46:21Z

Gcn4p binding site (Tang) samplings

← Older revision		Revision as of 20:46, 23 April 2026
Line 27:		Line 27:

	==Gcn4p binding site (Tang) samplings==		==Gcn4p binding site (Tang) samplings==
			[[Gcn4p gene transcriptions#Gcn4p binding site (Tang) samplings\|Gcn4p binding site (Tang) samplings]]

	Copying ATGACTC in "⌘F" yields none between ZNF497 and A1BG on the negative strand.		Copying ATGACTC in "⌘F" yields none between ZNF497 and A1BG on the negative strand.

Hypertension

2026-04-23T14:37:46Z

Modified the treatment section in line with the 2025 AHA/ACC guidelines for the management of hypertension

← Older revision		Revision as of 14:37, 23 April 2026
(2 intermediate revisions by the same user not shown)
Line 1:		Line 1:
	__NOTOC__		__NOTOC__
	{{SI}}		{{SI}}
	{{CMG}}; {{AE}} {{Sara.Zand}} {{USAMA}}		{{CMG}}; {{AE}} {{Sara.Zand}} {{USAMA}} {{HMA}}

	{{SK}} Blood pressure; hypertension; high blood pressure; systolic blood pressure; essential hypertension		{{SK}} Blood pressure; hypertension; high blood pressure; systolic blood pressure; essential hypertension
Line 858:		Line 858:
	:*[[Renin-angiotensin-convertng enzyme inhibitors]] ([[ACEI]] or [[ARB]])		:*[[Renin-angiotensin-convertng enzyme inhibitors]] ([[ACEI]] or [[ARB]])
	:*[[Thiazide-like diuretic]]		:*[[Thiazide-like diuretic]]
	::*~~[[Betablocker]] is~~ first line ~~therapy in the presence of~~ [[~~angina~~]] ~~and [[~~heart failure]].		::*Beta-blockers are not first-line for hypertension unless specific comorbidities (e.g., [[coronary heart disease]], heart failure with reduced ejection fraction) are present.
	::*Second-line lowering [[BP]] agents are used in resistant [[hypertension]] or specific conditions.		::*Second-line lowering [[BP]] agents are used in resistant [[hypertension]] or specific conditions

			* For Stage 2 hypertension (BP ≥140/90 mm Hg), initiation of antihypertensive therapy with two first-line agents of different classes, ideally in a single-pill combination, is recommended to improve blood pressure control and medication adherence.

	*The mainstay of therapy for [[resistant hypertension]] is:		*The mainstay of therapy for [[resistant hypertension]] is:
Line 865:		Line 867:
	:*Improving medications adherence		:*Improving medications adherence
	:*Diagnosis and treatment of the causes of [[secondary hypertension]]		:*Diagnosis and treatment of the causes of [[secondary hypertension]]
	:*Adding [[spironolactone]] or [[hydralazine]] or [[ minoxidil]] to first line therapy ([[CCB]]s, [[inhibitors of RAS]], [[chlorthalidone]].		:*Adding [[spironolactone]] or [[hydralazine]] or [[ minoxidil]] to first line therapy ([[CCB]]s, [[inhibitors of RAS]], [[chlorthalidone]]).
			:*Renal Denervation may be reasonable as an adjunct in select patients

	{{familytree/start}}		{{familytree/start}}
Line 874:		Line 877:
	{{familytree \| B01 \| \| \| B02 \| \| \| \| \| B03 \| \| \| \|B04\| \|B01=Nomal [[BP]] ([[BP]]<120/80 mmHg)\|B02=Elevated [[BP]] ([[BP]]120-129/<80mmHg)\|B03=Stage1 [[hypertension]](BP 130-139/80-89mmHg\|B04=Stage 2 [[hypertension]] ([[BP]]≥ 140/90}}		{{familytree \| B01 \| \| \| B02 \| \| \| \| \| B03 \| \| \| \|B04\| \|B01=Nomal [[BP]] ([[BP]]<120/80 mmHg)\|B02=Elevated [[BP]] ([[BP]]120-129/<80mmHg)\|B03=Stage1 [[hypertension]](BP 130-139/80-89mmHg\|B04=Stage 2 [[hypertension]] ([[BP]]≥ 140/90}}
	{{familytree \| \|!\| \| \| \| \|!\| \| \| \| \| \| \|!\| \| \| \| \|!\| }}		{{familytree \| \|!\| \| \| \| \|!\| \| \| \| \| \| \|!\| \| \| \| \|!\| }}
	{{familytree \| C01 \| \| \| C02 \| \| \| \| \| C03 \| \| \| \|C04\| \|C01=Life style modifications\|C02=Nonpharmocological therapy (class1)\|C03= 10 ~~years~~ cardiovascular disease ([[CVD]]) ~~risk≥ 10~~%\|C04=Non pharmacological therapy and [[BP]]lowering medication}}		{{familytree \| C01 \| \| \| C02 \| \| \| \| \| C03 \| \| \| \|C04\| \|C01=Life style modifications\|C02=Nonpharmocological therapy (class1)\|C03= 10-year cardiovascular disease (CVD) risk ≥7.5% by PREVENT\|C04=Non pharmacological therapy and [[BP]]lowering medication}}
	{{familytree \| \|!\| \| \| \| \|!\| \| \| \| \|,\|-\|^\|-\|.\| \| \|!\| \| \| \| \| \| \| \| \|}}		{{familytree \| \|!\| \| \| \| \|!\| \| \| \| \|,\|-\|^\|-\|.\| \| \|!\| \| \| \| \| \| \| \| \|}}
	{{familytree \| \|D01\| \| \| D02 \| \| \| D03 \| \| D04 \|!\| \| \| \| \| \| \| D01=Reevaulation in 1 year (class 2a)\|D02=Reevaulation in 3-6 months (class 1)\|D03= NO, nonpharmocological therapy (class1)\|D04= Yes,non pharmacological therapy and [[BP]] lowering medication}}		{{familytree \| \|D01\| \| \| D02 \| \| \| D03 \| \| D04 \|!\| \| \| \| \| \| \| D01=Reevaulation in 1 year (class 2a)\|D02=Reevaulation in 3-6 months (class 1)\|D03= NO, nonpharmocological therapy (class1)\|D04= Yes,non pharmacological therapy and [[BP]] lowering medication}}
Line 1,217:		Line 1,220:

	*[[Surgery\|Surgical]] procedure may be performed for patients with [[secondary hypertension]] such as [[coarctation of aorta]], [[Primary aldosteronism\|primary aldosteronism.]]		*[[Surgery\|Surgical]] procedure may be performed for patients with [[secondary hypertension]] such as [[coarctation of aorta]], [[Primary aldosteronism\|primary aldosteronism.]]
			*Renal Denervation may be reasonable as an adjunct in select patients with resistant hypertension or drug intolerance, but requires evaluation by a multidisciplinary team.

	===Prevention===		===Prevention===
Line 1,222:		Line 1,226:
	*Effective measures for the [[primary prevention]] of hypertension include: <ref name="WheltonCarey2018">{{cite journal\|last1=Whelton\|first1=Paul K.\|last2=Carey\|first2=Robert M.\|last3=Aronow\|first3=Wilbert S.\|last4=Casey\|first4=Donald E.\|last5=Collins\|first5=Karen J.\|last6=Dennison Himmelfarb\|first6=Cheryl\|last7=DePalma\|first7=Sondra M.\|last8=Gidding\|first8=Samuel\|last9=Jamerson\|first9=Kenneth A.\|last10=Jones\|first10=Daniel W.\|last11=MacLaughlin\|first11=Eric J.\|last12=Muntner\|first12=Paul\|last13=Ovbiagele\|first13=Bruce\|last14=Smith\|first14=Sidney C.\|last15=Spencer\|first15=Crystal C.\|last16=Stafford\|first16=Randall S.\|last17=Taler\|first17=Sandra J.\|last18=Thomas\|first18=Randal J.\|last19=Williams\|first19=Kim A.\|last20=Williamson\|first20=Jeff D.\|last21=Wright\|first21=Jackson T.\|title=2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines\|journal=Hypertension\|volume=71\|issue=6\|year=2018\|issn=0194-911X\|doi=10.1161/HYP.0000000000000065}}</ref>		*Effective measures for the [[primary prevention]] of hypertension include: <ref name="WheltonCarey2018">{{cite journal\|last1=Whelton\|first1=Paul K.\|last2=Carey\|first2=Robert M.\|last3=Aronow\|first3=Wilbert S.\|last4=Casey\|first4=Donald E.\|last5=Collins\|first5=Karen J.\|last6=Dennison Himmelfarb\|first6=Cheryl\|last7=DePalma\|first7=Sondra M.\|last8=Gidding\|first8=Samuel\|last9=Jamerson\|first9=Kenneth A.\|last10=Jones\|first10=Daniel W.\|last11=MacLaughlin\|first11=Eric J.\|last12=Muntner\|first12=Paul\|last13=Ovbiagele\|first13=Bruce\|last14=Smith\|first14=Sidney C.\|last15=Spencer\|first15=Crystal C.\|last16=Stafford\|first16=Randall S.\|last17=Taler\|first17=Sandra J.\|last18=Thomas\|first18=Randal J.\|last19=Williams\|first19=Kim A.\|last20=Williamson\|first20=Jeff D.\|last21=Wright\|first21=Jackson T.\|title=2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines\|journal=Hypertension\|volume=71\|issue=6\|year=2018\|issn=0194-911X\|doi=10.1161/HYP.0000000000000065}}</ref>

	:*[[Weight loss]]: ~~Reduction 1 mmHg~~ in ~~[[blood pressure]] for every one kilogram [[~~weight reduction]]		:*Weight loss: Sustained ≥5% reduction in body weight or ≥3 kg/m² reduction in BMI. Expect ~1 mmHg SBP drop per 1 kg lost
	:*[[Healthy diet]]: A [[diet]] rich in [[fruits]], [[vegetables]], [[whole grains]], [[low-fat dairy products]], reduced content of saturated and [[total fat]]		:*[[Healthy diet]]: A [[diet]] rich in [[fruits]], [[vegetables]], [[whole grains]], [[low-fat dairy products]], reduced content of saturated and [[total fat]]
	:*[[Reduced]] intake of dietary [[sodium]]: ~~Less than 1000-15000~~ mg/day		:*Reduced intake of dietary sodium: Target <2300 mg/day, with ideal limit <1500 mg/day
	:*Enhanced intake of [[dietary~~]][[~~ potassium]]:3500–5000 mg/d by intaking rich diet with [[~~potassium~~]]		:*Enhanced intake of dietary potassium: 3500–5000 mg/d by ideally intaking rich diet with potassium, or moderate supplementation (<80 mmol/day)
			:*Use of salt substitutes: Replace regular table/cooking salt with potassium-based salt substitutes. Avoid in [[CKD]] or with potassium-sparing drugs
			:*Reduced alcohol intake: Abstinence is optimal for BP control. If consumed, reduce intake by >50% to ≤1 drink/day for women or ≤2 drinks/day for men
	:*[[Physical activity]]: [[Aerobic]] ( 90–150 min/week), dynamic resistance (90–150 min/week), [[Isometric exercise\|Isometric]] resistance (4 × 2 min handgrip, 1 min rest between exercises, 3 sessions per week)		:*[[Physical activity]]: [[Aerobic]] ( 90–150 min/week), dynamic resistance (90–150 min/week), [[Isometric exercise\|Isometric]] resistance (4 × 2 min handgrip, 1 min rest between exercises, 3 sessions per week)
	:*~~Reduced [[alcohol]] intake~~: ~~Men ≤2 drinks daily, Women ≤1 drink daily~~		:*Stress reduction: Transcendental meditation (2 × 20 min/day) or device-guided slow breathing (<10 breaths/min for 15 min/day) may be reasonable adjuncts to lifestyle modification

	*Once diagnosed and treated, patients with hypertension are followed-up every month for evaluation of medication adherence and response to treatment.		*Once diagnosed and treated, patients with hypertension are followed-up every month for evaluation of medication adherence and response to treatment.

			=== Treatment Goal ===
			For all adults with confirmed hypertension, the recommended target is <130/80 mm Hg. For high-risk patients (10-year CVD risk ≥7.5% by PREVENT), achieving SBP <120 mm Hg is encouraged to reduce major adverse events.

	==References==		==References==